Product Data Sheet

Product Name: SF1126
Cat. No.: GC37633

Chemical Properties

Cas. No.	936487-67-1		
SMILES	N=C(N)NCCC[C@H](NC(CCC(OC[N+]1(CCOCC1)C(OC(C2=CC=C3)=C3C4=CC=CC=C4)=CC2=O)=O)=O)C(NCC(N[C@@H](CC([O-])=O)C(N[C@@H](CO)C(O)=O)=O)=O)=O		
Formula	$C_{39}H_{48}N_8O_{14}$	M.Wt	852.84
Solubility	Soluble in DMSO	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	SF1126		

Background

SF1126 is a clinically relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 prodrug, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis[1]. PI3K/BRD4[1]

SF1126 (0-6 μM; 48 hours) inhibits Hep3B, HepG2, SK-Hep1, and Huh7 cells proliferation with IC50s of 5.05, 6.89, 3.14, and 2.14 μM, respectively[1].SF1126 (1-10 μM; 24 hours) results in cell-cycle arrest with a proportional increase in G0-G1 and a decrease in the number of cells in the S-phase in Hep 3B, Hep G2, SK-Hep1, and Huh7 cells[1].SF1126 (0.5-2.5 μM; pre-30 minutes) and sorafenib suggests that combined treatment of SF1126 and sorafenib blocks multiple key enzymes in PI3K/AKT/mTOR and Ras/Raf/MAPK pathway[1]. Cell Viability Assay[1] Cell Line: Hep3B, HepG2, SK-Hep1, and Huh7 cells

[1]. Garlich JR, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 1;68(1):206-15.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA